Welcome to our dedicated page for Aimei Hlth Tech SEC filings (Ticker: AFJKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aimei Hlth Tech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aimei Hlth Tech's regulatory disclosures and financial reporting.
Aimei Health Technology Co., Ltd reported that Nasdaq notified the company on April 17, 2026 that it is out of compliance with Nasdaq Listing Rule 5250(c)(1) because it has not filed its Form 10-K for the year ended December 31, 2025. The report was due March 31, 2026, and a Form 12b-25 was filed on April 1, 2026. The notice does not immediately affect trading of Aimei’s ordinary shares, rights, or units on Nasdaq, but continued noncompliance could result in delisting.
The company has 60 days from the notice date to either file the annual report or submit a compliance plan, and may receive up to 180 days from the original due date if a plan is accepted. Aimei states it is working diligently to complete and file the Form 10-K and expects to regain compliance.
Aimei Health Technology Co., Ltd reported that Nasdaq notified the company on April 17, 2026 that it is out of compliance with Nasdaq Listing Rule 5250(c)(1) because it has not filed its Form 10-K for the year ended December 31, 2025. The report was due March 31, 2026, and a Form 12b-25 was filed on April 1, 2026. The notice does not immediately affect trading of Aimei’s ordinary shares, rights, or units on Nasdaq, but continued noncompliance could result in delisting.
The company has 60 days from the notice date to either file the annual report or submit a compliance plan, and may receive up to 180 days from the original due date if a plan is accepted. Aimei states it is working diligently to complete and file the Form 10-K and expects to regain compliance.
Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination with United Hydrogen Group Inc. by one month, moving the termination date from March 6, 2026 to April 6, 2026. To fund this sixteenth extension, a total of $34,330.96 was deposited into the company’s trust account for public shareholders, calculated as the lesser of $80,000 for all outstanding public shares or $0.033 per outstanding public share for the month.
In connection with the extension, the company issued an unsecured promissory note for $34,330.96 on March 4, 2026 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., with each contributing $17,165.48. The note bears no interest and becomes due when the business combination with United Hydrogen is completed. The payees may convert the note into private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one-fifth of one ordinary share, if they notify the company at least two business days before the business combination closes.
Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination with United Hydrogen Group Inc. by one month, moving the termination date from March 6, 2026 to April 6, 2026. To fund this sixteenth extension, a total of $34,330.96 was deposited into the company’s trust account for public shareholders, calculated as the lesser of $80,000 for all outstanding public shares or $0.033 per outstanding public share for the month.
In connection with the extension, the company issued an unsecured promissory note for $34,330.96 on March 4, 2026 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., with each contributing $17,165.48. The note bears no interest and becomes due when the business combination with United Hydrogen is completed. The payees may convert the note into private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one-fifth of one ordinary share, if they notify the company at least two business days before the business combination closes.
Aimei Health Technology Co., Ltd has extended the deadline to complete its initial business combination by one month, moving the termination date from February 6, 2026 to March 6, 2026. To fund this fifteenth monthly extension, an aggregate $34,330.96 was deposited into the company’s trust account for public shareholders.
In connection with this extension, the company issued an unsecured promissory note for $34,330.96 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., each contributing $17,165.48. The note bears no interest and becomes payable when the company consummates its proposed business combination with United Hydrogen. The payees may instead convert the note into private units of Aimei Health at $10.00 per unit immediately before closing, with each unit consisting of one ordinary share and a right to receive one-fifth of one ordinary share.
Aimei Health Technology Co., Ltd has extended the deadline to complete its initial business combination by one month, moving the termination date from February 6, 2026 to March 6, 2026. To fund this fifteenth monthly extension, an aggregate $34,330.96 was deposited into the company’s trust account for public shareholders.
In connection with this extension, the company issued an unsecured promissory note for $34,330.96 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., each contributing $17,165.48. The note bears no interest and becomes payable when the company consummates its proposed business combination with United Hydrogen. The payees may instead convert the note into private units of Aimei Health at $10.00 per unit immediately before closing, with each unit consisting of one ordinary share and a right to receive one-fifth of one ordinary share.
Mizuho Financial Group, Inc. has filed Amendment No. 3 to its Schedule 13G stating that it now beneficially owns 0 common shares of Aimei Health Technology Co., Ltd., representing 0.0% of the common share class as of 12/31/2025.
The filing reports no sole or shared voting or dispositive power over Aimei’s common shares. Mizuho is identified as a parent holding company, and notes that related entities may have been indirect beneficial owners through a wholly owned subsidiary, Mizuho Securities USA LLC.
Mizuho Financial Group, Inc. has filed Amendment No. 3 to its Schedule 13G stating that it now beneficially owns 0 common shares of Aimei Health Technology Co., Ltd., representing 0.0% of the common share class as of 12/31/2025.
The filing reports no sole or shared voting or dispositive power over Aimei’s common shares. Mizuho is identified as a parent holding company, and notes that related entities may have been indirect beneficial owners through a wholly owned subsidiary, Mizuho Securities USA LLC.